News
Events
Research
Ways to help
About us
Contact Us
Home >
>
DONATE NOW
EVENTS
ANNUAL BALL
CONTACT US
SIGN UP TO NEWSLETTER
Jun 2014
Predicting MS in children
Oct 2014
Three new Incubator Grants announced
Dec 2014
2015 Funding announced
Mar 2015
Investigating new treatment options
Oct 2015
Progress in MS Research Conference
Feb 2016
2016 Round of Funding
Feb 2014
New projects being funded
Feb 2014
Breakthrough study shows great promise

PrevANZ Progress  

 

MS Research Australia’s landmark PrevANZ vitamin D MS prevention trial is continuing to make steady progress, and has reached the exciting milestone of 110 patients enrolled in the trial towards our target of 240 participants.

The international MS research community continues to watch the trial with great anticipation, as this trial will provide the much needed evidence as to whether vitamin D supplementation can have a clinical benefit for people at high risk of MS.

Professor Bill Carroll, Chair of the PrevANZ Clinical Trial Steering Committee said, “This study remains unique and the MS research community globally is very aware of the study, and extremely interested in its results. Understanding whether Vitamin D, and at what dose, is effective in preventing MS inflammation and relapses will potentially improve healthcare for people at risk of MS everywhere in the world”.

The PrevANZ clinical trial is examining whether vitamin D supplementation can delay or prevent a second attack of neurological symptoms in people who have experienced a first episode (known as a first demyelinating event or clinically isolated syndrome) which puts them at high risk of developing MS.

While there is a great deal of evidence that low blood levels of vitamin D are associated with an increased risk of developing MS, there is as yet no definitive evidence that vitamin D supplementation, and at what optimal dose, is effective to prevent the development of MS.

Australia has a critical mass of expertise in this field and MS Research Australia has worked with researchers to develop this carefully designed trial. The trial is funded by MS Research Australia, with the support of the state MS Societies, including significant contributions from the MS Society of WA, MS Queensland, Trish MS Research Foundation, Foundation 5 Million Plus and other trusts and foundations. The trial enrolled the first participant in June 2013, and while recruitment has been steady, it has been a little slower than anticipated and a number of innovative recruitment strategies are being implemented.

Twenty sites around Australia and New Zealand are involved in the trial and two new sites with high recruitment potential have been established in Adelaide and the Sydney Eye Hospital. Results are now expected in 2018.

Anyone wishing to learn more about the trial can visit www.msra.org.au/prevanz

Trish Foundation & MS Research Australia Working together to find a cure for MS
Copyright © Trish Multiple Sclerosis Research Foundation. All rights reserved.